-

Abstract

Although bisphosphonates have been proven to cause osteonecrosis, most oncological patients’ medications are not limited to bisphosphonates. Dentists should be aware of the other drugs that these patients might use and their potential to raise the risk of osteonecrosis. The aim this paper is to emphasize the possible complications that oncologic drugs can cause during dental procedures.

Keywords

• Osteonecrosis, bisphosphonate, sunitinib

BİSFOSFONAT VE BİRLİKTE KULLANILAN SİSTEMİK İLAÇLARA BAĞLI OSTEONEKROZLAR Osteonecrosis Due to Use of Bisphosphonates and Other Systemic Drugs

Abstract

ÖZ
Bisfosfonat kullanımının osteonekroza neden olabileceği literatürde belgelenmiş olsa da, çoğu onkolojik
hastanın kullandığı ilaçlar bisfosfonatlarla sınırlı değildir. Diş hekimlerinin onkolojik hastaların
kullanabileceği ve bisfosfonatların neden olduğu osteonekroz riskini arttırabilecek diğer ilaçlardan da
haberdar olması gerekir. Bu makalenin amacı bu tür ilaçların onkolojik hastalarda dental girişimler
sırasında komplikasyona yol açabilecek potansiyele sahip olduğunu vurgulamaktır.
Anahtar kelimeler: Osteonekroz, bisfosfonat, sunitinib
ABSTRACT
Although bisphosphonates have been proven to cause osteonecrosis, most oncological patients'
medications are not limited to bisphosphonates. Dentists should be aware of the other drugs that these
patients might use and their potential to raise the risk of osteonecrosis. The aim this paper is to emphasize
the possible complications that oncologic drugs can cause during dental procedures.
Keywords: Osteonecrosis, bisphosphonate, sunitinib

Keywords

• Osteonekroz, bisfosfonat, sunitinib

References

1. Almazrooa SA, Woo SB. Bisphosphonate and nonbisphosphonate-associated osteonecrosis of the jaw: a review. J Am Dent Assoc, 2009 Jul; 140(7): 864-75. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg, 2007 Mar; 65(3): 369-76. Lam DK, Sándor GK, Holmes HI, Evans AW, Clokie CM. A review of bisphosphonate-associated osteonecrosis of the jaws and its management. J Can Dent Assoc, 2007 Jun; 73(5): 417-22. Pazianas M. Osteonecrosis of the jaw and the role of macrophages. J Natl Cancer
2. Inst, 2011 Feb 2; 103(3): 232-40. Dannemann C, Grätz KW, Riener MO, Zwahlen RA. Jaw osteonecrosis related to bisphosphonate therapy: a severe secondary disorder. Bone, 2007 Apr; 40(4): 828-34. Hoefert S, Eufinger H. Sunitinib may raise the risk of bisphosphonate-related osteonecrosis of the jaw: presentation of three cases. Oral Surg Oral Med Oral Pathol Oral
3. Radiol Endod, 2010 Oct; 110(4): 463-69. Magopoulos C, Karakinaris G, Telioudis Z, Vahtsevanos K, Dimitrakopoulos I, Antoniadis K, Delaroudis S. Osteonecrosis of the jaws due to bisphosphonate use: a review of 60 cases and treatment proposals. Am J Otolaryngol, 2007 May-Jun; 28(3): 158-63. Migliorati CA, Covington JS 3rd. New oncology drugs and osteonecrosis of the jaw (ONJ). J Tenn Dent Assoc, 2009 Fall; 89(4): 36Migliorati CA. Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol, 2003 Nov 15; 21(22): 4253-54.
4. Migliorati CA, Siegel MA, Elting LS. Bisphosphonate-associated osteonecrosis: a long term complication of bisphosphonate treatment. Lancet Oncol, 2006 Jun; 7(6): 508Tanvetyanon T, Stiff PJ. Management of adverse effects associated with intravenous bisphosphonates. Ann Oncol, 2006; 17: 897-907.
5. Rutkowski JL. Combined use of glucocorticoids and bisphosphonates may increase severity of bisphosphonate-related osteonecrosis of the jaw. J Oral Implantol, 2011 Oct; 37(5): 505.
6. Koch FP, Walter C, Hansen T, Jäger E, Wagner W. Osteonecrosis of the jaw related to sunitinib. Oral Maxillofac Surg, 2011 Mar; 15(1): 63-66.
7. Ayllon J, Launay-Vacher V, Medioni J, Cros C, Spano JP, Oudard S. Osteonecrosis of the jaw under bisphosphonate and antiangiogenic therapies: cumulative toxicity profile? Ann Oncol, 2009 Mar; 20(3): 600-601. Bozas G, Roy A, Ramasamy V, Maraveyas A. Osteonecrosis of the jaw after a single bisphosphonate infusion in a patient with metastatic renal cancer treated with sunitinib. Onkologie, 2010; 33(6): 321-23. Brunello A, Saia G, Bedogni A, Scaglione D, Basso U. Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma. Bone, 2009 Jan; 44(1): 173-75.
8. Christodoulou C, Pervena A, Klouvas G, Galani E, Falagas ME, Tsakalos G, Visvikis A, Nikolakopoulou A, Acholos V, Karapanagiotidis G, Batziou E, Skarlos DV. Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology, 2009; 76(3): 209-11. Troeltzsch M, Woodlock T, Kriegelstein S, Steiner T, Messlinger K, Troeltzsch M. Physiology and pharmacology of nonbisphosphonate drugs implicated in osteonecrosis of the jaw. J Can Dent Assoc, 2012; 78: c85. Fleissig Y, Regev E, Lehman H. Sunitinib related osteonecrosis of jaw: a case report. Oral Surg Oral Med Oral Pathol Oral

9. Radiol, 2012 Mar; 113(3): e1-3. Agrillo A, Nastro Siniscalchi E, Facchini A, Filiaci F, Ungari C. Osteonecrosis of the jaws in patients assuming bisphosphonates and sunitinib: two case reports. Eur Rev
10. Med Pharmacol Sci, 2012 Jul; 16(7): 952-57. Nicolatou-Galitis O, Migkou M, Psyrri A, Bamias A, Pectasides D, Economopoulos T, Raber-Durlacher JE, Dimitriadis
11. G, Dimopoulos MA. Gingival bleeding and jaw bone necrosis in patients with metastatic renal cell carcinoma receiving sunitinib: report of 2 cases with clinical implications. Oral Surg Oral Med Oral Pathol Oral Radiol, 2012 Feb; 113(2): 234-38. Yazışma Adresi: Mert Tayşi
12. İİstanbul Üniversitesi Diş Hekimliği Fakültesi Ağız, Diş ve Çene Cerrahisi A.D. 34093 Çapa-Fatih/İSTANBUL Tel [phone] e-posta: [e-mail]